Primary hyperoxaluria type 1 ? liver transplantation before end-stage renal disease?

1993 ◽  
Vol 7 (3) ◽  
pp. 326-327 ◽  
Author(s):  
Jon I. Scheinman
Nephron ◽  
2001 ◽  
Vol 87 (1) ◽  
pp. 80-84 ◽  
Author(s):  
T. David-Walek ◽  
C. Niederstadt ◽  
P.M. Rob ◽  
L. Fricke ◽  
K. Latta ◽  
...  

2015 ◽  
Vol 28 (1) ◽  
pp. 60-67
Author(s):  
Yukiko Mori ◽  
Soichi Tamamura ◽  
Kenta Yamada ◽  
Sosuke Ooto ◽  
Yasuhiro Watanabe ◽  
...  

Author(s):  
Bernd Hoppe ◽  
Patricia A Pellikka ◽  
Bastian Dehmel ◽  
Ana Banos ◽  
Elisabeth Lindner ◽  
...  

Abstract Background In primary hyperoxaluria Type 1 (PH1), endogenous oxalate overproduction significantly elevates urinary oxalate excretion, resulting in recurrent urolithiasis and/or progressive nephrocalcinosis and often early end-stage renal disease (ESRD). In ESRD, dialysis cannot sufficiently remove oxalate; plasma oxalate (Pox) increases markedly, inducing systemic oxalate deposition (oxalosis) and often death. Interventions to reduce Pox in PH1 subjects with ESRD could have significant clinical impact. This ongoing Phase II, open-label trial aimed to evaluate whether long-term Oxabact™ (Oxalobacter formigenes, OC5, OxThera Intellectual Property AB, Sweden) lowers Pox in PH1 ESRD subjects, ameliorating clinical outcome. Methods PH1 ESRD subjects on stable dialysis regimens were examined. Subjects were administered one OC5 capsule twice daily for up to 36 months or until transplantation. Total Pox values, cardiac function and safety were evaluated. Free Pox was evaluated in a comparative non-treated PH1 dialysis group using retrospective chart reviews and analyses. Results Twelve subjects enrolled in an initial 6-week treatment phase. Following a washout of up to 4 weeks, eight subjects entered a continuation study; outcomes after 24 months of treatment are presented. After 24 months, all subjects had reduced or non-elevated Pox compared with baseline. Cardiac function improved, then stabilized. No treatment-related serious adverse events were reported. Conclusions Compared with an untreated natural control cohort, 24 months OC5 administration was beneficial to PH1 ESRD subjects by substantially decreasing Pox concentrations, and improving or stabilizing cardiac function and clinical status, without increasing dialysis frequency. OC5 was safe and well-tolerated.


2017 ◽  
Vol 56 (205) ◽  
pp. 175-178
Author(s):  
Ren Qingqi ◽  
Ju Weiqiang ◽  
Wang Dongping ◽  
Guo Zhiyong ◽  
Chen Maogen ◽  
...  

Primary hyperoxaluria type 1 is an autosomal recessive hereditary glyoxylate metabolism disorder characterized by excessive production of oxalate, caused by the deficiency of liver specific peroxisomal enzyme: alanineglyoxylate aminotransferase. For patients with end-stage renal disease, combined liver and kidney transplantation was needed. This report describes one patient, with a diagnosis of end-stage renal disease and primary hyperoxaluria 1 confirmed by PCR and direct sequencing with genomic DNA, received the simultaneous combined liver and kidney transplantation after seven months’ waiting. However, there were several complications observed post surgery, such as protracted bleeding, common bile duct anastomotic stenosis, biliary calculi and recurrence of urolithiasis. All these were well solved by relevant department, and finally a satisfactory outcome was achieved. Multidisciplinary cooperation plays an important role on the PH1 patient management, especially when multiple complications are encountered. Keywords: primary hyperoxaluria type 1; end-stage renal disease; liver transplantation; kidney transplantation.


2021 ◽  
Vol 105 (4) ◽  
pp. e46-e47
Author(s):  
Arnaud Devresse ◽  
Nathalie Godefroid ◽  
Blaise Anthonissen ◽  
Laura Labriola ◽  
Catherine de Magnée ◽  
...  

2000 ◽  
Vol 4 (3) ◽  
pp. 177-181 ◽  
Author(s):  
Daniela Nolkemper ◽  
Markus J. Kemper ◽  
Martin Burdelski ◽  
Irith Vaismann ◽  
Xavier Rogiers ◽  
...  

2015 ◽  
Vol 1 (1) ◽  
pp. napoc.2015.1467
Author(s):  
Mohammed Hameed ◽  
Kashif Eqbal ◽  
Beena Nair ◽  
Alexander Woywodt ◽  
Aimun Ahmed

Primary hyperoxaluria type 1 (PH1) is a rare, inherited, autosomal recessive, metabolic disorder caused by a deficiency of peroxisomal alanine-glyoxylate aminotransferase (AGT). We describe here a case of a 57-year-old man with End Stage Renal Disease, where the late age of presentation of PH T1 due to marked heterogeneity of disease expression caused a delay in diagnosis, and we discuss the causes of the poor outcome typical of this condition


Sign in / Sign up

Export Citation Format

Share Document